News

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

An analysis of CLEAR Outcomes and CTTC data suggest bempedoic acid holds its own relative to statin therapy for cardiovascular risk reduction normalized to 1 mmol/L reduction in LDL-C.

Online survey data underlines notable discrepancies across various aspects of ID screening and supplementation in clinical practice for patients with HF.

These findings also highlighted the necessity of identifying the clinically relevant comorbidities of asthma and allergic rhinitis in a proactive manner.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.

These updated guidelines by the AAAAI and ACAAI Joint Task Force incorporate additional research regarding treatment options for eczema.

Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.

Marking the end of a voluntary recall, the FDA approved updates to Susvimo regarding the ocular implant and refill needle.

Iron deficiency and anemia rates were typically higher in less economically developed regions and rural areas in China.

These findings confirm the ways in which patient responses in the head and neck areas contribute to modifications in life quality among those with eczema.

Emerging treatments for CSA include hypochlorite phrenic nerve stimulation and pharmacological intervention, Badr told HCPLive.

Chehade reviews key findings from the phase 3 EoE kids trial and how they inform dupilumab’s use in children 1-11 years of age with eosinophilic esophagitis.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Our fourth and final quiz on the ESC/EAS 2019 guidelines on dyslipidemia spotlights lifestyle and nonpharmacological intervention recommendations.

Long-term exposure to proton pump inhibitors and oral anticoagulants was linked to an increased risk of IDA presentation.

This retrospective study highlighted the results of Singaporean atopic dermatitis patients aged 18 years and below who had undergone phototherapy.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.

The biosimilars month in review underscores the efficacy and safety of biosimilars in rheumatology, including recent studies supporting the growing confidence in these treatments across disease spaces.

Patients with chronic kidney disease and TSAT levels of 30–40% experienced significantly fewer cardiovascular events than those with TSAT of 20–30%.

This analysis from Spain assessed the short-term effectiveness and safety of abrocitinib within a real-world setting for those with moderate-to-severe eczema.

Our dermatology FDA recap for the first half of 2024 includes our top 5 approvals, 3 decisions to watch in the second half of 2024, and a podcast episode with James Del Rosso, DO

Cook explains to HCPLive how elite athletes can optimize sleep for peak performance.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.